News
Public · Published
uniQure Wins FDA Priority Review for Huntington's Gene Therapy BLA
uniQure said the FDA accepted its application for ifezuntirgene inilparvovec, a gene therapy for Huntington's disease, for Priority Review under the Accelerated Approval pathway. The FDA set a target decision date of May 1, 2027, and is tentatively planning an Advisory Committee discussion, though its date and timing are not finalized.
Published:
Updated:
What happened
uniQure said the FDA accepted its application for ifezuntirgene inilparvovec, a gene therapy for Huntington’s disease, for Priority Review under the Accelerated Approval pathway. The FDA set a target decision date of May 1, 2027, and is tentatively planning an Advisory Committee discussion, though its date and timing are not finalized.
Confirmed
Global impact / market context
Priority Review and the target decision date bring a defined regulatory step, but do not mean the therapy is approved. If authorization follows, patient access and sales could depend on the FDA decision and evidence from the planned confirmatory trial, which is intended to test benefit in about 200 patients.
Analyst inference
The application relies on previously announced 36-month Phase I/II results compared with an external control, a group outside the trial used for comparison. That evidence supports the filing, while the planned randomized confirmatory study may be important to whether the FDA considers the treatment’s benefit adequately established.
Confirmed
What to watch
- Watch for the FDA to finalize whether an Advisory Committee will meet and set its date; the agency has only tentatively planned a discussion so far. Confirmed
- uniQure plans to begin U.S. patient screening by the end of 2026 for the confirmatory trial, which is planned to enroll about 200 patients. Confirmed
- The FDA’s target decision date is May 1, 2027; a decision could clarify whether the therapy can reach patients, but approval is not assured. Analyst inference
Evidence
- Original source link unavailable